Alerts will be sent to your verified email
Verify Email
UNJHAFOR
|
Unjha Formulations
|
Parmax Pharma
|
Beryl Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
10.34 % | -1068.03 % | 3.64 % |
|
5yr average Equity Multiplier
|
1.62 | 29.23 | 2.12 |
|
5yr Average Asset Turnover Ratio
|
3.51 | 1.05 | 1.19 |
|
5yr Avg Net Profit Margin
|
1.88 % | -11.29 % | 1.13 % |
|
Price to Book
|
2.76 | 0.0 | 1.26 |
|
P/E
|
11.78 | 0.0 | 53.04 |
|
5yr Avg Cash Conversion Cycle
|
18.8 Days | -92.25 Days | -589.78 Days |
|
Inventory Days
|
28.57 Days | 69.37 Days | 36.09 Days |
|
Days Receivable
|
41.04 Days | 20.01 Days | 112.55 Days |
|
Days Payable
|
53.92 Days | 296.94 Days | 964.25 Days |
|
5yr Average Interest Coverage Ratio
|
17.56 | -0.77 | 1.91 |
|
5yr Avg ROCE
|
19.44 % | -14.3 % | 7.2 % |
|
5yr Avg Operating Profit Margin
|
3.19 % | 2.43 % | 6.72 % |
|
5 yr average Debt to Equity
|
0.0 | 10.96 | 0.59 |
|
5yr CAGR Net Profit
|
32.6 % | n/a | 19.3 % |
|
5yr Average Return on Assets
|
6.62 % | -9.05 % | 1.98 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
36.92 % | 30.8 % | 26.38 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | 1.46 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Unjha Formulations
|
Parmax Pharma
|
Beryl Drugs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|